Antineoplastic drugs, also known as anticancer drugs, anti-malignant drugs, refer to drugs for the treatment of malignant tumors.
Simply put, there are chemotherapy drugs and biological agents. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of tumors; the invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry, and genetic engineering have accelerated the process of drug development; research and development of anti-tumor drugs have been Enter a new era.
At present, there are more than 80 kinds of anti-cancer drugs commonly used in clinical practice in the world, which can be roughly divided into the following 6 categories: cytotoxic drugs, hormone drugs, biological response modifiers, monoclonal antibody drugs, other drugs, and auxiliary drugs.
In 2019, the market size of Anticancer Drugs is 89300 million US$ and it will reach 163400 million US$ in 2025, growing at a CAGR of 7.9% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Anticancer Drugs.
This report studies the global market size of Anticancer Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Anticancer Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
F. Hoffmann-La Roche Ltd
Eli Lilly and Company
CELGENE CORPORATION
Novartis AG
Pfizer Inc
Amgen Inc
Bayer AG
AstraZeneca
Takeda Pharmaceutical Company Limited
Merck & Co.
Market Segment by Product Type
Cytotoxic Drugs (Alkylating Agents, and Antimetabolites)
Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors)
Hormonal Drugs
Market Segment by Application
Lung Cancer
Breast Cancer
Leukemia
Colorectal Cancer
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Anticancer Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Anticancer Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Anticancer Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Summary:
Get latest Market Research Reports on AnticancerDrugs. Industry analysis & Market Report on AnticancerDrugs is a syndicated market report, published as Global (United States, European Union and China) Anticancer Drugs Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of AnticancerDrugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.